257 related articles for article (PubMed ID: 15615091)
1. Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies.
Van Lint C; Quivy V; Demonté D; Chariot A; Vanhulle C; de Walque S; Gaudray G; Veithen E; Bours V; Piette J; Burny A
Bull Mem Acad R Med Belg; 2004; 159(Pt 2):176-89. PubMed ID: 15615091
[TBL] [Abstract][Full Text] [Related]
2. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
3. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.
Vandergeeten C; Quivy V; Moutschen M; Van Lint C; Piette J; Legrand-Poels S
Biochem Pharmacol; 2007 Jun; 73(11):1738-48. PubMed ID: 17386923
[TBL] [Abstract][Full Text] [Related]
6. Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency.
Munier S; Delcroix-Genête D; Carthagéna L; Gumez A; Hazan U
Retrovirology; 2005 Nov; 2():73. PubMed ID: 16305739
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives.
Stevens M; Balzarini J; Lagoja IM; Noppen B; François K; Van Aerschot A; Herdewijn P; De Clercq E; Pannecouque C
Virology; 2007 Aug; 365(1):220-37. PubMed ID: 17459445
[TBL] [Abstract][Full Text] [Related]
8. HIV reservoirs, latency, and reactivation: prospects for eradication.
Dahl V; Josefsson L; Palmer S
Antiviral Res; 2010 Jan; 85(1):286-94. PubMed ID: 19808057
[TBL] [Abstract][Full Text] [Related]
9. [Molecular basis of HIV-1 latency - Part II: HIV-1 reactivation and therapeutic implications].
Cherrier T; Le Douce V; Redel L; Marban C; Aunis D; Rohr O; Schwartz C
Med Sci (Paris); 2010 Mar; 26(3):291-5. PubMed ID: 20346279
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
[TBL] [Abstract][Full Text] [Related]
11. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells.
Thierry S; Gozlan J; Jaulmes A; Boniface R; Nasreddine N; Strauss F; Maréchal V
AIDS; 2007 Jan; 21(3):283-92. PubMed ID: 17255735
[TBL] [Abstract][Full Text] [Related]
13. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
[TBL] [Abstract][Full Text] [Related]
14. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression.
Victoriano AF; Imai K; Togami H; Ueno T; Asamitsu K; Suzuki T; Miyata N; Ochiai K; Okamoto T
FEBS Lett; 2011 Apr; 585(7):1103-11. PubMed ID: 21402072
[TBL] [Abstract][Full Text] [Related]
15. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies.
Quivy V; Adam E; Collette Y; Demonte D; Chariot A; Vanhulle C; Berkhout B; Castellano R; de Launoit Y; Burny A; Piette J; Bours V; Van Lint C
J Virol; 2002 Nov; 76(21):11091-103. PubMed ID: 12368351
[TBL] [Abstract][Full Text] [Related]
17. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification.
Imai K; Ochiai K; Okamoto T
J Immunol; 2009 Mar; 182(6):3688-95. PubMed ID: 19265147
[TBL] [Abstract][Full Text] [Related]
19. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
20. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
